Clinical Trials Register

Summary
EudraCT Number:	2018-000783-29
Sponsor's Protocol Code Number:	GBR830-204
National Competent Authority:	Lithuania - SMCA
Clinical Trial Type:	EEA CTA
Trial Status:	Prematurely Ended
Date on which this record was first entered in the EudraCT database:	2019-12-19
Trial results	View results

Index
A. PROTOCOL INFORMATION
B. SPONSOR INFORMATION
C. APPLICANT IDENTIFICATION
D. IMP IDENTIFICATION
D.8 INFORMATION ON PLACEBO
E. GENERAL INFORMATION ON THE TRIAL
F. POPULATION OF TRIAL SUBJECTS
G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
P. END OF TRIAL

Expand All Collapse All

A. Protocol Information

A.1

Member State Concerned

Lithuania - SMCA

A.2

EudraCT number

2018-000783-29

A.3

Full title of the trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of GBR 830 in Adult Subjects with Moderate to Severe Atopic Dermatitis.

A.3.1

Title of the trial for lay people, in easily understood, i.e. non-technical, language

A Study of GBR 830 in Adult Patients with Atopic Dermatitis

A.4.1

Sponsor's protocol code number

GBR830-204

A.7

Trial is part of a Paediatric Investigation Plan

A.8

EMA Decision number of Paediatric Investigation Plan

B. Sponsor Information
B.Sponsor: 1
B.1.1	Name of Sponsor	Inchos Sciences SA (renamed from Glenmark Pharmaceuticals SA)
B.1.3.4	Country	Switzerland
B.3.1 and B.3.2	Status of the sponsor	Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1	Name of organisation providing support	Inchos Sciences SA
B.4.2	Country	Switzerland
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1	Name of organisation	TMC Pharma Services Ltd
B.5.2	Functional name of contact point	Regulatory Services
B.5.3	Address:
B.5.3.1	Street Address	Lodge Farm Barn, Elvetham Park Estate, Fleet
B.5.3.2	Town/ city	Hartley Wintney, Hampshire
B.5.3.3	Post code	RG27 8AS
B.5.3.4	Country	United Kingdom
B.5.4	Telephone number	+441252842255
B.5.5	Fax number	+441252842277
B.5.6	E-mail	regulatory.services@tmcpharma.com

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3	IMP Role	Test
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	No
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.2	Product code	GBR 830
D.3.4	Pharmaceutical form	Powder for solution for infusion
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Subcutaneous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	GBR 830
D.3.9.1	CAS number	2126777-87-3
D.3.9.2	Current sponsor code	GBR 830
D.3.9.3	Other descriptive name	GBR 830 is a highly selective, humanized monoclonal antibody (mAb) of the IgG1 subtype against the human OX40 (CD134) receptor.
D.3.9.4	EV Substance Code	SUB192421
D.3.10	Strength
D.3.10.1	Concentration unit	mg/ml milligram(s)/millilitre
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	150
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	No
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	Yes
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	Yes
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No

D.8 Information on Placebo
D.8 Placebo: 1
D.8.1	Is a Placebo used in this Trial?	Yes
D.8.3	Pharmaceutical form of the placebo	Powder for solution for infusion
D.8.4	Route of administration of the placebo	Subcutaneous use

E. General Information on the Trial

E.1 Medical condition or disease under investigation

E.1.1

Medical condition(s) being investigated

Moderate to severe atopic dermatitis

E.1.1.1

Medical condition in easily understood language

Moderate to severe eczema

E.1.1.2

Therapeutic area

Diseases [C] - Immune System Diseases [C20]

MedDRA Classification

E.1.2 Medical condition or disease under investigation

E.1.2	Version	21.1
E.1.2	Level	LLT
E.1.2	Classification code	10003639
E.1.2	Term	Atopic dermatitis
E.1.2	System Organ Class	100000004858

E.1.3

Condition being studied is a rare disease

E.2 Objective of the trial

E.2.1

Main objective of the trial

To characterize the efficacy of GBR 830 monotherapy in adults with moderate-to-severe atopic dermatitis (AD) compared to placebo as measured by Investigator’s Global Assessment (IGA).

E.2.2

Secondary objectives of the trial

To evaluate the proportion of subjects with Eczema Area and Severity Index (EASI) 75 (≥75% improvement from baseline) at Week 16.
To evaluate safety, tolerability, pharmacokinetics (PK), and immunogenicity of GBR 830 monotherapy in adults with moderate-to-severe AD.
To measure the effect of GBR 830 on disease activity in adult subjects with moderate-to-severe AD, as measured by validated tools (EASI response, SCORing Atopic Dermatitis [SCORAD]).

E.2.3

Trial contains a sub-study

E.3

Principal inclusion criteria

1. Provided written informed consent and any locally required authorization prior to any protocol-related procedures, including screening evaluations.
2. Willing and able to comply with all aspects of the protocol.
3. Male or female ≥18 years at the time of screening.
4. Physician diagnosis of AD for > 1 year; diagnosis of AD as defined by the American Academy of Dermatology Consensus Criteria (Eichenfeld et al, 2014).
5. AD involvement of ≥10% Body surface area (BSA) at screening and baseline.
6. EASI score of ≥12 at screening or ≥16 at baseline.
7. IGA score of ≥3 at screening and baseline (on the 0 to 4 IGA scale, in which 3 is moderate and 4 is severe).
8. Baseline NRS score for maximum itch intensity ≥3 over the previous 24 hours. A minimum of 3 days of diary completion is required in the week prior to randomization.
9. Documented/reported recent history (within 6 months before the screening visit) of inadequate response to treatment with topical medications (topical corticosteroids or crisaborole or topical calcineurin inhibitors) or for whom topical treatments are otherwise medically inadvisable (eg, because of important side effects or safety risks as defined in the protocol). Documents may include medical records, physician to healthcare provider communication (with date and time of communication and physician signature), or, pharmacy records (with clearly listed dates of dispensation). A course of marketed systemic immunosuppressants (eg, prednisone, cyclosporine, methrotrexate) for AD in the 6 months prior to screening assumes failure of topicals and is acceptable in place of topical failure.
10. Have applied a stable dose of topical emollient (moisturizer) twice-daily for at least 7 consecutive days immediately before the baseline visit (with the exception of prohibited moisturizers containing additives listed in Exclusion Criteria #5).
11. Must agree to the following requirements during the study:
a. If female and of childbearing potential, she must have a negative serum pregnancy test result within 7 days prior to first dosing and a negative urine pregnancy test predose on Day 1. She must be willing to use a highly effective form of contraception (ICH E8 Guideline, 1997; (ICH M3 [R2] Guidance, 2009; (FDA M3 [R2] Guidance, 2010) for the duration of the study and for at least 3 months after the last dose of study medication. Methods like periodic abstinence, post ovulation procedures and withdrawal are not considered adequate. Each woman will be considered to have childbearing potential unless she has been surgically sterilized by hysterectomy or bilateral tubal ligation/salpingectomy or has been post-menopausal for at least 2 years. For postmenopausal women only, follicle stimulating hormone (FSH) testing will be performed at screening to confirm non-childbearing potential (FSH ≥40 IU/L).
b. If male with a partner of childbearing potential, he must be willing to use condoms in combination with a second effective method of contraception during the study. Each man will be considered as potent unless surgically sterilized (with appropriate post vasectomy documentation of the absence of sperm in the ejaculate). Male subjects must continue to use contraception for 180 days following administration of the study drug.
c. Male subjects should agree not to donate sperm during the study and for 180 days following administration of the study drug.

E.4

Principal exclusion criteria

1. Prior treatment with GBR 830.
2. Employee of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals.
3. Concurrent enrollment in another investigational clinical study.
4. Treatment with any of the following before baseline: d. Investigational biological agent within 8 weeks of baseline or 5 half-lives, whichever is longer.
e. Investigational drugs eg, phosphodiesterase type 4 (PDE4) inhibitors, Janus kinase (JAK) inhibitors, within 4 weeks of baseline.
f. Phototherapy for AD within 4 weeks of baseline.
g. Marketed drugs, including systemic corticosteroids, immunosuppressive/immunomodulatory drugs including but not limited to cyclosporine, mycophenolate-mofetil, interferon-gamma (IFN-γ), PDE4 inhibitors, JAK inhibitors, azathioprine or methotrexate within 4 weeks of baseline.
h. Topical medications, including corticosteroids, tacrolimus, and/or pimecrolimus, and crisaborole within 1 week of baseline.
i. Regular use (>2 visits/week) of a tanning booth/parlor within 4 weeks of baseline.
j. Biologics, depending on the type of biologic such as cell-depleting agents including but not limited to rituximab: within 6 months of baseline, or until lymphocyte and CD19+ lymphocyte count returns to normal, whichever is longer.
k. Biologics including infliximab, adalimumab, golimumab, certolizumab pegol, abatacept, etanercept, anakinra, dupilumab: within 12 weeks of baseline, or 5 half-lives, whichever is longer.
l. Other biologics: within 5 half-lives (if known).
5. Initiation of treatment of AD with prescription moisturizers or moisturizers containing additives such as ceramide, hyaluronic acid, urea, or filaggrin degradation products during the screening period (subjects may continue using stable doses of such moisturizers if initiated before the screening visit).
6. Planned or anticipated use of any prohibited medications and procedures during study treatment as defined in the study protocol.
7. Subjects who are immunocompromised (congenital or acquired), or who have had a recent (within 3 months prior to baseline) or current serious systemic infection (including infectious mononucleosis-like illness or herpes zoster).
8. Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.
9. Subjects who have evidence of active or latent tuberculosis (TB) as documented in their medical history or test positive at screening. For indeterminate cases, an informed decision will be made between the Principal Investigator and Medical Monitor.
10. Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the baseline visit, or superficial skin infections within 1 week before the baseline visit. NOTE: subjects may be rescreened after infection resolves.
11. Presence of skin comorbidities that may interfere with study assessments, in the opinion of the Investigator, including subjects with psoriasis.
12. Poorly controlled asthma as assessed by the Asthma Control Questionnaire [ACQ] based on International ERS/ATS guidelines.
13. Any condition at baseline which is part of the criteria for discontinuation of study drug as defined in the study protocol.
14. Subjects who are known to be seropositive for human immunodeficiency virus (HIV) or who test positive at screening.
15. History of a positive result for Hepatitis B surface antigen (HBsAg), antibody to Hepatitis B core antigen (anti-HBcAg), or antibody to Hepatitis C virus (anti-HCV) or presence of and of these findings at screening.
16. History of alcohol or drug abuse within 2 years of the screening visit.
17. Subjects with a history of non-malignant lymphoproliferative disorders, or a history of malignancy within 5 years before baseline (except completely treated in situ cervical carcinoma or non-metastatic squamous or basal cell carcinoma of the skin).
18. In the opinion of the Investigator, subjects with any other medical or psychological condition as well as laboratory values, which are significantly different from normal reference ranges and/or judged to be clinically significant; and/or any condition that would interfere with evaluation of the study drug or interpretation of subject safety or study results, including conditions that are inadequately understood at the time of screening.
19. Subjects with a history of substance abuse or dependence that in the opinion of the Investigator, is considered to interfere with the subject’s participation in the study.
20. Planned or anticipated major surgical procedure during the subject’s participation in this study.
21. Women who are pregnant or breast feeding.
22. Known hypersensitivity to monoclonal antibodies or any of the excipients of the study drug.

E.5 End points

E.5.1

Primary end point(s)

Proportion of subjects with both IGA 0 or 1 (on a 5-point scale) and an IGA reduction from baseline of ≥2 points at Week 16.

E.5.1.1

Timepoint(s) of evaluation of this end point

Day 1, Week 16 (Day 113)

E.5.2

Secondary end point(s)

• Proportion of subjects with EASI-75 (≥75% improvement from baseline) at Week 16 (key secondary endpoint).
• Dose response of GBR 830 evaluated by percent change from baseline in EASI.
• Proportion of patients with improvement (reduction) of pruritus Numerical Rating Scale (pruritus Numerical Rating Scale (NRS) ≥4 from baseline to Week 16.
• Proportion of subjects who achieve an EASI 50 (≥50% improvement from baseline) response from baseline through Week 16.
• Change in SCORAD from baseline through Week 16.
• Change in the Dermatology Life Quality Index (DLQI) from baseline through Week 16.
• Change in Global Individual Signs Score (GISS) (erythema, infiltration/population, excoriations, lichenification) from baseline through Week 16.
• Change in Hospital Anxiety Depression Scale (HADS) from baseline through Week 16.
• Change in Patient Oriented Eczema Measure (POEM) from baseline through Week 16.
• Absolute and percent change in Patient Global Assessment of Disease from baseline through Week 16.
• Absolute and percent change in Patient Global Assessment of Treatment from baseline through Week 16.
• Assessment of sick leave and/or missed school days through Week 16.
Safety Endpoints:
• Incidence of TEAEs from baseline through Week 16 and Week 54.
• Incidence of skin infection TEAEs requiring systemic treatment from baseline through Week 16 and Week 54.
• Incidence of conjunctivitis TEAEs requiring systemic treatment from baseline through Week 16 and Week 54.
Incidence of treatment-emergent SAEs from baseline through Week 16 and Week 54.
• Incidence of TEAEs leading to treatment discontinuation from baseline through Week 16 and Week 54.
• Overall number of TEAEs and SAEs through Week 16 and Week 54.
• Vital signs, clinical laboratory values, and ECG results monitored from baseline through Week 16 and Week 54.
• Formation of ADA to GBR 830 to evaluate immunogenicity.
Pharmacokinetics Endpoints:
• Cmax, tmax, AUC0-tau, AUC from time 0 to the last measurable concentration (AUC0-t), and other related parameters will be estimated
using data from the rich PK group. from the blinded treatment phase. Ctrough values will be estimated using data from both rich and sparse
PK groups from the blinded treatment phase.

E.5.2.1

Timepoint(s) of evaluation of this end point

Efficacy: Day 1, Week 16 (Day 113)
Safety: Day 1, Week 16 (Day 113) and Week 54 (Day 379)

E.6 and E.7 Scope of the trial

E.6

Scope of the trial

E.6.1

Diagnosis

E.6.2

Prophylaxis

E.6.3

Therapy

Yes

E.6.4

Safety

Yes

E.6.5

Efficacy

Yes

E.6.6

Pharmacokinetic

Yes

E.6.7

Pharmacodynamic

Yes

E.6.8

Bioequivalence

E.6.9

Dose response

E.6.10

Pharmacogenetic

E.6.11

Pharmacogenomic

Yes

E.6.12

Pharmacoeconomic

E.6.13

Others

E.7

Trial type and phase

E.7.1

Human pharmacology (Phase I)

E.7.1.1

First administration to humans

E.7.1.2

Bioequivalence study

E.7.1.3

Other

E.7.1.3.1

Other trial type description

E.7.2

Therapeutic exploratory (Phase II)

Yes

E.7.3

Therapeutic confirmatory (Phase III)

E.7.4

Therapeutic use (Phase IV)

E.8 Design of the trial

E.8.1

Controlled

Yes

E.8.1.1

Randomised

Yes

E.8.1.2

Open

E.8.1.3

Single blind

E.8.1.4

Double blind

Yes

E.8.1.5

Parallel group

Yes

E.8.1.6

Cross over

E.8.1.7

Other

E.8.2

Comparator of controlled trial

E.8.2.1

Other medicinal product(s)

E.8.2.2

Placebo

Yes

E.8.2.3

Other

E.8.2.4

Number of treatment arms in the trial

E.8.3

The trial involves single site in the Member State concerned

E.8.4

The trial involves multiple sites in the Member State concerned

Yes

E.8.4.1

Number of sites anticipated in Member State concerned

E.8.5

The trial involves multiple Member States

Yes

E.8.5.1

Number of sites anticipated in the EEA

E.8.6 Trial involving sites outside the EEA

E.8.6.1

Trial being conducted both within and outside the EEA

Yes

E.8.6.2

Trial being conducted completely outside of the EEA

E.8.6.3

If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned

Bulgaria

Canada

Czech Republic

Germany

Latvia

Lithuania

Poland

United States

E.8.7

Trial has a data monitoring committee

Yes

E.8.8

Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial

LVLS

E.8.9 Initial estimate of the duration of the trial

E.8.9.1

In the Member State concerned years

E.8.9.1

In the Member State concerned months

E.8.9.1

In the Member State concerned days

E.8.9.2

In all countries concerned by the trial years

E.8.9.2

In all countries concerned by the trial months

F. Population of Trial Subjects

F.1 Age Range

F.1.1

Trial has subjects under 18

F.1.1.1

In Utero

F.1.1.2

Preterm newborn infants (up to gestational age < 37 weeks)

F.1.1.3

Newborns (0-27 days)

F.1.1.4

Infants and toddlers (28 days-23 months)

F.1.1.5

Children (2-11years)

F.1.1.6

Adolescents (12-17 years)

F.1.2

Adults (18-64 years)

Yes

F.1.2.1

Number of subjects for this age range:

234

F.1.3

Elderly (>=65 years)

Yes

F.1.3.1

Number of subjects for this age range:

234

F.2 Gender

F.2.1

Female

Yes

F.2.2

Male

Yes

F.3 Group of trial subjects

F.3.1

Healthy volunteers

F.3.2

Patients

Yes

F.3.3

Specific vulnerable populations

Yes

F.3.3.1

Women of childbearing potential not using contraception

F.3.3.2

Women of child-bearing potential using contraception

Yes

F.3.3.3

Pregnant women

F.3.3.4

Nursing women

F.3.3.5

Emergency situation

F.3.3.6

Subjects incapable of giving consent personally

F.3.3.7

Others

F.4 Planned number of subjects to be included

F.4.1

In the member state

F.4.2

For a multinational trial

F.4.2.1

In the EEA

258

F.4.2.2

In the whole clinical trial

468

F.5

Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)

None. The study includes an open- label treatment period of up to 38 weeks which will allow continued treatment of patients who complete the blinded phase Day 113 (Week 16) end-of-treatment visit.

G. Investigator Networks to be involved in the Trial

N. Review by the Competent Authority or Ethics Committee in the country concerned

Competent Authority Decision

Authorised

Date of Competent Authority Decision

2020-02-13

Ethics Committee Opinion of the trial application

Favourable

Ethics Committee Opinion: Reason(s) for unfavourable opinion

Date of Ethics Committee Opinion

2020-01-08

P. End of Trial
P.	End of Trial Status	Prematurely Ended
P.	Date of the global end of the trial	2021-08-03

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials